27/04/2023 – Presentation on masitinib in amyotrophic lateral sclerosis delivered at the American Academy of Neurology 2023 Annual Meeting Download PDF Post navigationPreviousPrevious post:Success of the capital increase by private placement for an amount of 15 million eurosNextNext post:Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual MeetingRelated PostsAB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development SummitMay 17, 2023AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letterMay 9, 2023Annual financial results as of 31 December, 2022April 28, 2023Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual MeetingApril 27, 2023Success of the capital increase by private placement for an amount of 15 million eurosApril 24, 2023Implementation of a new strategy and launch of a capital increaseApril 21, 2023
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development SummitMay 17, 2023
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letterMay 9, 2023
